Pharmaceutical

FDA clears Krystal Biotech’s IND for Type 1 AATD treatment KB408

A Phase I trial exploring the gene therapy in patients with alpha-1 antitrypsin deficiency is expected to start in Q1 2024.

Sep 23, 2023 - 20:00
FDA clears Krystal Biotech’s IND for Type 1 AATD treatment KB408
A Phase I trial exploring the gene therapy in patients with alpha-1 antitrypsin deficiency is expected to start in Q1 2024.
Read the original article

Tags:

Previous Article

STAT+: Travere kidney drug narrowly fails confirmatory trial following FDA approval

Next Article

Jazz Pharma’s Enrylaze wins European approval for AML and LBL

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

UK charities condemn continued drug shortages

UK charities condemn continued drug shortages

Apr 13, 2024

STAT+: FDA gives a mixed response to a petition seeking greater clinical trial transparency

STAT+: FDA gives a mixed response to a petition seeking...

Feb 23, 2024

STAT+: Backed by Mayo Clinic and Microsoft, a nonprofit forms to test AI tools used in health care

STAT+: Backed by Mayo Clinic and Microsoft, a nonprofit...

Jan 8, 2024